SIILTIBCY® is a tuberculosis skin test approved in European Union that detects tuberculosis infection regardless of BCG vaccination status with demonstrated sensitivity and specificity Full marketing authorisation granted by the…

The SLS Europe team, alongside Serum Institute of India Pvt. Ltd., participated in the TBVI Symposium in Les Diablerets, contributing to discussions on the future of TB vaccine development. Our…

SIILTIBCY® is poised to be the first skin test in Europe that accurately detects TB, regardless of BCG vaccination status EMA has given a positive recommendation, with a final decision…

Dr. Fabio Pisano is our new Chief Development Officer. With his extensive experience and invaluable contributions to our company, Fabio will continue to drive innovation and strategic growth of SLS…

We are pleased to announce a new partnership between Serum Life Science Europe GmbH (SLS Europe) and INCATE (INCubator for Antibacterial Therapies Europe) in the ongoing battle against antimicrobial resistance…

SLS Europe team, together with Serum Institute of India Pvt. Ltd., presented our leading TB vaccine, VPM1002, contributing to global discussions on TB vaccine innovation. Active engagement and collaboration with…

Collaborating with Serum Institute of India Pvt. Ltd., we are proud partners in advancing the groundbreaking TB vaccine candidate, VPM1002. For deeper insights into our efforts, explore BBC’s coverage on…

With a round of applause and a plethora of insights, Day 2 marks the exciting conclusion of our priMe trial meeting in Entebbe, Uganda.   Highlights of Day Two: Collective…

TUSANYUSE NYO OBALABA (Welcome everyone in Luganda language) The first day at the annual meeting of the pivotal priMe trial held in Entebbe, Uganda, was marked by significant discussions and…